These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

704 related articles for article (PubMed ID: 36765684)

  • 21. Immune Cell Modulation of the Extracellular Matrix Contributes to the Pathogenesis of Pancreatic Cancer.
    Ahmad RS; Eubank TD; Lukomski S; Boone BA
    Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34204306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-resolution 3D visualization of nanomedicine distribution in tumors.
    Moss JI; Barjat H; Emmas SA; Strittmatter N; Maynard J; Goodwin RJA; Storm G; Lammers T; Puri S; Ashford MB; Barry ST
    Theranostics; 2020; 10(2):880-897. PubMed ID: 31903157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploring the tumor microenvironment with nanoparticles.
    Miao L; Huang L
    Cancer Treat Res; 2015; 166():193-226. PubMed ID: 25895870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An MMP-2 Responsive Liposome Integrating Antifibrosis and Chemotherapeutic Drugs for Enhanced Drug Perfusion and Efficacy in Pancreatic Cancer.
    Ji T; Li S; Zhang Y; Lang J; Ding Y; Zhao X; Zhao R; Li Y; Shi J; Hao J; Zhao Y; Nie G
    ACS Appl Mater Interfaces; 2016 Feb; 8(5):3438-45. PubMed ID: 26759926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Boosting Nanomedicine Efficacy with Hyperbaric Oxygen Therapy.
    Wang X; Li S; Liu X; Wu X; Ye N; Yang X; Li Z
    Adv Exp Med Biol; 2021; 1295():77-95. PubMed ID: 33543456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The PDAC Extracellular Matrix: A Review of the ECM Protein Composition, Tumor Cell Interaction, and Therapeutic Strategies.
    Perez VM; Kearney JF; Yeh JJ
    Front Oncol; 2021; 11():751311. PubMed ID: 34692532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antifibrotic therapy to normalize the tumor microenvironment.
    Hauge A; Rofstad EK
    J Transl Med; 2020 May; 18(1):207. PubMed ID: 32434573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. From Passive Targeting to Personalized Nanomedicine: Multidimensional Insights on Nanoparticles' Interaction with the Tumor Microenvironment.
    Sebak AA; El-Shenawy BM; El-Safy S; El-Shazly M
    Curr Pharm Biotechnol; 2021; 22(11):1444-1465. PubMed ID: 33308126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells.
    Lee HO; Mullins SR; Franco-Barraza J; Valianou M; Cukierman E; Cheng JD
    BMC Cancer; 2011 Jun; 11():245. PubMed ID: 21668992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathophysiological role of microRNA-29 in pancreatic cancer stroma.
    Kwon JJ; Nabinger SC; Vega Z; Sahu SS; Alluri RK; Abdul-Sater Z; Yu Z; Gore J; Nalepa G; Saxena R; Korc M; Kota J
    Sci Rep; 2015 Jun; 5():11450. PubMed ID: 26095125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy.
    Shi Y; van der Meel R; Chen X; Lammers T
    Theranostics; 2020; 10(17):7921-7924. PubMed ID: 32685029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thermosensitive Liposomal Codelivery of HSA-Paclitaxel and HSA-Ellagic Acid Complexes for Enhanced Drug Perfusion and Efficacy Against Pancreatic Cancer.
    Wei Y; Wang Y; Xia D; Guo S; Wang F; Zhang X; Gan Y
    ACS Appl Mater Interfaces; 2017 Aug; 9(30):25138-25151. PubMed ID: 28696100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of tumor microenvironments on targeted delivery of glycol chitosan nanoparticles.
    Yhee JY; Jeon S; Yoon HY; Shim MK; Ko H; Min J; Na JH; Chang H; Han H; Kim JH; Suh M; Lee H; Park JH; Kim K; Kwon IC
    J Control Release; 2017 Dec; 267():223-231. PubMed ID: 28917532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclopamine treatment disrupts extracellular matrix and alleviates solid stress to improve nanomedicine delivery for pancreatic cancer.
    Zhang B; Wang H; Jiang T; Jin K; Luo Z; Shi W; Mei H; Wang H; Hu Y; Pang Z; Jiang X
    J Drug Target; 2018 Dec; 26(10):913-919. PubMed ID: 29533111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulating the tumor microenvironment with new therapeutic nanoparticles: A promising paradigm for tumor treatment.
    Zhang Y; Ho SH; Li B; Nie G; Li S
    Med Res Rev; 2020 May; 40(3):1084-1102. PubMed ID: 31709590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Extracellular Matrix and Pancreatic Cancer: A Complex Relationship.
    Weniger M; Honselmann KC; Liss AS
    Cancers (Basel); 2018 Sep; 10(9):. PubMed ID: 30200666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor-Targeted Nanomedicine for Immunotherapy.
    Cabral H; Kinoh H; Kataoka K
    Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined cancer therapeutics-Tackling the complexity of the tumor microenvironment.
    Roma-Rodrigues C; Raposo LR; Valente R; Fernandes AR; Baptista PV
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Sep; 13(5):e1704. PubMed ID: 33565269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pancreatic Tumor Microenvironment.
    Wang K; He H
    Adv Exp Med Biol; 2020; 1296():243-257. PubMed ID: 34185297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancement of tumour penetration by nanomedicines through strategies based on transport processes and barriers.
    Yang H; Tong Z; Sun S; Mao Z
    J Control Release; 2020 Dec; 328():28-44. PubMed ID: 32858072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.